Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. **(Original)** A compound of formula I, or a pharmaceutically acceptable salt thereof,



I

wherein:

Z^1 is N or CH;

Z^2 and Z^3 are each independently N or CR^7;

R^1, R^2, R^3, R^4, R^5, R^6, and R^7 are each independently H, R^8, or R^9;

each R^8 is independently a hydrocarbyl group; and

each R^9 is independently halo, NO_2, alkoxy, CN, CF_3, SO_3H, $SO_2NR^{10}R^{11}$, SO_2R^{12}, $NR^{13}R^{14}$, $(CH_2)_aCOOR^{15}$, $(CH_2)_bCONR^{16}R^{17}$, $(CH_2)_cCOR^{18}$ or $(CH_2)_dOH$;

a, b, c and d are each independently 0, 1 2 3 or 4;

$R^{10\text{-}18}$ are each independently H or alkyl;

provided that when R^1 and R^2 are both H,

Z^1 is CH; or

Z^2 is N; or

Z^1 is CH and Z^2 is N;

and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.

2. **(Original)** A compound according to claim 1 wherein each R^8 is independently a $C_{1\text{-}30}$ hydrocarbyl group, optionally containing up to twelve heteroatoms selected from N, S, and O, and optionally bearing up to six substituents each independently selected from halo, NO_2, CN, CF_3, SO_3H, SO_2NH_2, SO_2Me, OH, NH_2, COOH, and $CONH_2$.

3. **(Currently Amended)** A compound according to claim 1 ~~or claim 2~~ wherein each R^8 is independently an alkyl group, an aryl group or a cycloheteroalkyl group.

4. **(Currently Amended)** A compound according to claim 1 ~~or claim 2~~ wherein each R^9 is independently halo, NO_2, alkoxy, CN, CF_3, SO_3H, SO_2NH_2, SO_2Me, OH, NH_2, $(CH_2)_aCOOR^{15}$, $(CH_2)_dOH$, $CONH_2$ or COR^{18}.

5. **(Currently Amended)** A compound according to ~~any preceding~~ claim 1 wherein:
R^1 is H, alkyl, aryl, $(CH_2)_aCOOR^{15}$ or OH;
R^2 is H, $(CH_2)_dOH$, $(CH_2)_aCOOR^{15}$, COR^{18} or alkyl;
R^3 is halo, H, alkoxy, cycloheteroalkyl, alkyl or OH;
R^4 is H, NH_2, OH, alkyl, CF_3 or NO_2; and
R^5 and R^6 are both H.

6. **(Currently Amended)** A compound according to ~~any preceding~~ claim 1 wherein:
R^1 is H, Me, Ph, CH_2COOMe or OH;
R^2 is H, $(CH_2)_2OH$, COOEt, COMe or Me;
R^3 is Cl, H, OMe, N-morpholinyl, N-pyrrolidinyl, Me or OH;
R^4 is H, NH_2, OH, Me, CF_3 or NO_2; and
R^5 and R^6 are both H.

7. **(Original)** A compound according to claim 1 wherein Z^1 is CH and Z^2 and Z^3 are each independently N or CR^7.

8. **(Original)** A compound according to claim 7 wherein Z^2 and Z^3 are each independently CR^7.

9. **(Currently Amended)** A compound according to claim 7 ~~or claim 8~~ wherein;
R^1 is alkyl or OH;
R^2 is alkyl or COR^{18};
R^3 is OH or halo; and
Z^2 and Z^3 are both CH.

10. **(Original)** A compound according to claim 9 wherein R^1 is Me or OH, R^2 is COMe or Me, and R^3 is OH or Cl.

11. **(Original)** A compound according to claim 1 wherein Z^1 is N and Z^2 and Z^3 are each independently N or CR^7.

12. **(Original)** A compound according to claim 11 wherein Z^2 and Z^3 are each independently CR^7.

13. **(Original)** A compound according to claim 12 wherein:
R^1 is alkyl, aryl, OH or $(CH_2)_aCOOR^{15}$;
R^2 is COR^{18}, H, $COOR^{15}$ or alkyl;
R^3 is halo, H, OH, alkyl or morpholino;
R^4 is H, NH_2, OH, CF_3 or NO_2; and
Z^2 and Z^3 are both CH.

14. **(Original)** A compound according to claim 13 wherein:
R^1 is Me, Ph, OH or CH_2COOMe;
R^2 is COMe, H, COOEt or Me; and
R^3 is halo, H, OH, alkyl or morpholino.

15. **(Original)** A compound according to claim 11 wherein Z^2 is N and Z^3 is CR^7.

16. **(Original)** A compound according to claim 15 wherein:
R^1 is H, OH or alkyl;
R^2 is H, $(CH_2)_dOH$, alkyl, $(CH_2)_aCOOR^{15}$, COR^{18};
R^3 is halo, alkoxy or heterocycloalkyl;
R^4 is H or alkyl; and
Z^3 is CH.

17. **(Original)** A compound according to claim 16 wherein:
R^1 is H, OH or Me;
R^2 is H, $(CH_2)_2OH$, Me, COOEt, COMe;
R^3 is halo, OMe or N-pyrrolidinyl;
R^4 is H or Me; and
Z^3 is CH.

18. **(Original)** A compound according to claim 1 which is selected from the following:
1-{2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-5-yl}-ethanone

(4-Chloro-phenyl)-[4-(4-methyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
(4-Chloro-phenyl)-[4-(4-phenyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazole-5-carboxylic acid ethyl ester
{2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-thiazol-4-yl}-acetic acid methyl ester
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester
N-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-benzene-1,3-diamine
3-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(3-trifluoromethyl-phenyl)-amine
(4-Chloro-3-trifluoromethyl-phenyl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine
(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
1-{2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-methyl-thiazol-5-yl}-ethanone
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(6-methoxy-pyridin-3-yl)-amine
(6-Chloro-pyridin-3-yl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(4-morpholin-4-yl-phenyl)-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(4-methyl-3-nitro-phenyl)-amine
4-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol
(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol
(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

19. (**Original**) A compound according to claim 1 which is selected from the following:
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester;
N-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-benzene-1,3-diamine
3-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(3-trifluoromethyl-phenyl)-amine

(4-Chloro-3-trifluoromethyl-phenyl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(6-methoxy-pyridin-3-yl)-amine
2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol
(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol
(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

20. (**Original**) A compound according to claim 1 which is selected from the following:
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester;
(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine; and
(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol
(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol
(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

21. (**Original**) A compound according to claim 1 which is (6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

22. (**Currently Amended**) A pharmaceutical composition comprising a compound according to ~~any preceding~~ claim 1 admixed with a pharmaceutically acceptable diluent, excipient or carrier.

Claims 23-41 (**Canceled**).

42. **(Currently Amended)** Use of a compound according to ~~any one of~~ claims 1 ~~to 21~~ in an assay for identifying further candidate compounds capable of inhibiting one or more of a cyclin dependent kinase, aurora kinase, GSK and a PLK enzyme.

43. **(Currently Amended)** Use according to claim 42~~38~~ wherein said assay is a competitive binding assay.

44. **(Original)** A process for preparing a compound of formula I as defined in claim 1, said process comprising reacting a compound of formula 9 with a compound of formula 10 to form a compound of formula I, wherein R^{1-6} are as defined in claim 1



9 10 I

45. **(Original)** A process for preparing a compound of formula I as defined in claim 1, said process comprising reacting a compound of formula 15 with a compound of formula 3 to form a compound of formula I, wherein R^{1-6} are as defined in claim 1



15 3 I

46. **(New)** A method of treating a proliferative disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the proliferative disorder is treated.

47. **(New)** The method of claim 46, wherein the proliferative disorder is cancer or leukemia.

48. **(New)** The method of claim 46, wherein the proliferative disorder is glomerulonephritis, rheumatoid arthritis, psoriasis or chronic obstructive pulmonary disorder.

49. **(New)** A method of treating a viral disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the viral disorder is treated.

50. **(New)** The method according to claim 49, wherein the viral disorder is selected from human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV).

51. **(New)** A method of treating a CNS disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the CNS disorder is treated.

52. **(New)** The method according to claim 51, wherein the CNS disorder is Alzheimer's disease or bipolar disorder.

53. **(New)** A method of treating alopecia, said method comprising administering to a subject in need thereof, a compound of claim 1, such that alopecia is treated.

54. **(New)** A method of treating a stroke, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the stroke is treated.

55. **(New)** The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit at least one PLK enzyme.

56. **(New)** The method according to claim 55, wherein the PLK enzyme is PLK1.

57. **(New)** The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit at least one CDK enzyme.

58. **(New)** The method according to claim 57, wherein the CDK enzyme is CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and/or CDK9.

59. **(New)** The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit aurora kinase.

60. **(New)** A method of treating diabetes, said method comprising administering to a subject in need thereof, a compound of claim 1, such that diabetes is treated.

61. **(New)** The method according to claim 60, wherein the diabetes is non-insulin-dependent diabetes or Type II diabetes.

62. **(New)** The method according to claim 60, wherein the compound is administered in an amount sufficient to inhibit GSK.

63. **(New)** The method according to claim 62, wherein the compound is administered in an amount sufficient to inhibit GSK3β.

64. **(New)** A method of treating an inflammatory disease, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the inflammatory disease is treated.

65. **(New)** A method of treating an infectious disease, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the infectious disease is treated.